comparemela.com

Page 7 - Kelsey Kirk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

argenx Highlights Strategic Priorities for 2022

Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications

United statesKelsey kirkMichelle greenblattBeth delgiaccoVan hauwermeirenTim van hauwermeirenZai labDrug administrationExchange commissionEuropean medicines agencyDevices agency of marketing authorization applicationHealth canadaImmunology innovation programJapan pharmaceuticalsEuronext nasdaqChief executive officer

argenx Highlights Strategic Priorities for 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesKelsey kirkBeth delgiaccoVan hauwermeirenTim van hauwermeirenZai labDrug administrationExchange commissionEuropean medicines agencyDevices agency of marketing authorization applicationHealth canadaImmunology innovation programJapan pharmaceuticalsChief executive officerMedical devices agencyMarketing authorization application

argenx to Present at 40th Annual J P Morgan Healthcare Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Kelsey kirkMichelle greenblattBeth delgiaccoTim van hauwermeirenImmunology innovation programChief executive officerHealthcare conferenceGlobe newswire

argenx to Present at 40th Annual J P Morgan Healthcare Conference

03.01.2022 - January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive .

Kelsey kirkMichelle greenblattBeth delgiaccoTim van hauwermeirenImmunology innovation programHealthcare conferenceChief executive officerInnovation programChief executive

argenx Announces U S Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

United statesUnited kingdomKelsey kirkMichelle greenblattHoward jf jrBeth delgiaccoExchange commissionZai labDrug administrationImmunology innovation programMyasthenia gravisDaily livingImportant safety informationPrescribing informationNorth americaTherapeutics targets

vimarsana © 2020. All Rights Reserved.